FXCM expands Stock Baskets offering with seven new baskets

LONDON and SYDNEY, Australia and JOHANNESBURG, South Africa, Feb. 02, 2021 (GLOBE NEWSWIRE) — FXCM Group, LLC ("FXCM Group' or "FXCM'), the leading international provider of online foreign exchange trading, CFD trading, cryptocurrencies and related services, is today announcing a further expansion of its Stock Basket offering to customers. FXCM previously introduced a portfolio of Stock Baskets in May 2020 and are now expanding this offering with the addition of seven new baskets.

Currently, FXCM offers six Stock Baskets to its retail clients. These feature some of the most widely traded companies globally and are made up into the following: Big US Tech ("FAANG"), Esports & Gaming, Biotechnology, Cannabis, China Technology and China E–commerce. These baskets have proven to be popular with their customers and as a result they are expanding this area with a host of new products.

The new sectors added include Airlines, Casinos, Travel & Hospitality, US Automotive, US Banks, US E–commerce, and "Work From Home'.

FXCM's Stock Basket products combine the shares of multiple companies from one sector into a single tradeable instrument. This allows customers to speculate on sectors as a whole instead of having to depend on the performance of a single company.

For example, the "Work From Home' basket combines the companies that have become front and centre of every day life for many under lockdown, including Zoom Video Communications Inc, Slack Technologies Inc, Twilio Inc, as well as Chewy Inc and Peloton Interactive Inc. With these companies having prospered during the pandemic, there was a lot of interest from FXCM's customers to invest in them. The "Work From Home' basket pools these companies and allows for smaller investors to invest some of these key companies.

The list of companies and weightings is available on FXCM's stock basket website: (https://www.fxcm.com/uk/stock–baskets/).

This announcement follows on from a year which saw FXCM launch US, UK and European Single Shares trading, with the broker expected to add trading on more individual company stocks and new exchanges throughout 2021.

Brendan Callan, CEO of FXCM said: "We are always looking to create new opportunities for our customers to capitalise on, and this is continued with these new baskets reflecting some of the industries that have seen the biggest market movement during the pandemic. Their addition to our offering will provide our customers with the ability to speculate on the fluctuation of companies that have dominated the headlines throughout 2020 in a more cost–effective way, while minimising their risk by spreading exposure across multiple stocks in just a single click."

About FXCM:

FXCM is a leading provider of online foreign exchange (FX) trading, CFD trading, and related services. Founded in 1999, the company's mission is to provide global traders with access to the world's largest and most liquid market by offering innovative trading tools, hiring excellent trading educators, meeting strict financial standards and striving for the best online trading experience in the market. Clients have the advantage of mobile trading, one–click order execution and trading from real–time charts. In addition, FXCM offers educational courses on FX trading and provides trading tools, proprietary data and premium resources. FXCM Pro provides retail brokers, small hedge funds and emerging market banks access to wholesale execution and liquidity, while providing high and medium frequency funds access to prime brokerage services via FXCM Prime. FXCM is a Leucadia Company.

Forex Capital Markets Limited: FCA registration number 217689 (www.fxcm.com/uk)

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.

74.74% of retail investor accounts lose money when trading CFDs with this provider.

You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

FXCM EU LTD: CySEC license number 392/20 (www.fxcm.com/eu)

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.

The vast majority of retail investor accounts lose money when trading CFDs.

You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

FXCM Australia Pty. Limited: AFSL 309763. Losses can exceed your deposited funds. The products may not be suitable for all investors. Please ensure that you fully understand the risks involved. If you decide to trade products offered by FXCM AU, you must read and understand the Financial Services Guide, Product Disclosure Statement, and Terms of Business on www.fxcm.com/au.

FXCM South Africa (PTY) Ltd: FSP No 46534 (www.fxcm.com/za). Our service includes products that are traded on margin and carry a risk of losses in excess of your deposited funds. The products may not be suitable for all investors. Please ensure that you fully understand the risks involved.

FXCM Markets Limited: Losses can exceed deposited funds. (www.fxcm.com/markets).

Media contact:

Chatsworth Communications
+44 (0) 20 7440 9780
fxcm@chatsworthcommunications.com


GLOBENEWSWIRE (Distribution ID 8145003)

Nyxoah and Vanderbilt University enter exclusive licensing agreement regarding next generation neurostimulation technologies to treat Obstructive Sleep Apnea (OSA)

PRESS RELEASE

Nyxoah and Vanderbilt University enter exclusive licensing agreement regarding next generation neurostimulation technologies to treat Obstructive Sleep Apnea (OSA)

Mont–Saint–Guibert, Belgium "" 2nd February, 2021 "" Nyxoah SA (Euronext: NYXH) ("Nyxoah" or the "Company"), a health–technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces the Company has signed an exclusive license agreement with Vandebilt University, Nashville "" TN, USA.
The agreement allows Nyxoah to further develop new neurostimulation technologies for the treatment of sleep disordered breathing conditions that were invented by Dr. David T. Kent. New treatments will focus, among others, on stimulating the ansa cervicalis, the efferent fiber of the glossopharyngeal nerve or nerves that innervate the palatoglossus and/or the palatopharyngeus muscle. Nyxoah will also work together with Vanderbilt University to continue prosecution of patent applications, which will give Nyxoah the exclusive right to use these new technologies once patents will be granted.
Nyxoah agreed to pay Vanderbilt an up–front fee as well as payments based on regulatory, development and commercialization milestones. Nyxoah also agreed to pay royalties on future product sales.
Under this agreement, Nyxoah shall develop a next generation neurostimulation–based solution to treat Obstructive Sleep Apnea patients. Obstructive Sleep Apnea is the most common sleep disordered breathing condition, affecting almost 1 billion people globally1. Over the past decade, neurostimulation therapies, such as the proprietary Genio system developed and commercialized by Nyxoah, have proven their long–term efficacy in efficiently treating OSA patients.

Olivier Taelman, Chief Executive Officer of Nyxoah, commented: "We are delighted to start collaborating with Vanderbilt University, a worldwide recognized US university in this field of research, through this exclusive licensing agreement. This will open new horizons in the field of neurostimulation technologies, improving and expanding current treatment solutions for OSA patients, and will reinforce Nyxoah's future pipeline. The upcoming collaboration with Dr. Kent at Vanderbilt University Medical Center, together with Nyxoah's groundbreaking approach in neurostimulation and its collaboration with international key opinions leaders, will help Nyxoah strengthen its position as innovator offering patient–centered solutions."

Dr. David T. Kent from Vanderbilt University added: "Partnering with Nyxoah creates the opportunity to build new technologies based on Vanderbilt's intellectual property. We share the same vision of developing disruptive solutions, always having in mind that patients should be put at the center. Our mission will be to demonstrate the unique potential of such new technologies resulting in a broader OSA treatment portfolio."

– ENDS –

For further information, please contact:

Nyxoah
Milena Venkova, Corporate Communications Manager
milena.venkova@nyxoah.com
+32 490 11 93 57

About Nyxoah

Nyxoah is a healthtech company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA). Nyxoah's lead solution is the Genio system, a CE–validated, patient–centered, next generation hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk2 and comorbidities including cardiovascular diseases, depression and stroke.
Following the successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio system received its European CE Mark in 2019. The Company is currently conducting the BETTER SLEEP study in Australia and New Zealand for therapy indication expansion, the DREAM IDE pivotal study for FDA approval and a post–marketing EliSA study in Europe to confirm the long–term safety and efficacy of the Genio system.
For more information, please visit www.nyxoah.com.

About Vanderbilt University
Vanderbilt University, located in Nashville "" Tennessee, USA, is a private research university offering a full range of undergraduate, graduate and professional degrees.
For more information, please visit www.vanderbilt.edu.

Caution "" Genio is CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.


1 Benjafield, Adam V et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature–based analysis. Lancet Respir Med 2019 Published Online July 9, 2019 http://dx.doi.org/10.1016/S2213–2600(19)30198–5

2 Young T. et al: Sleep Disordered Breathing and Mortality: Eighteen–Year Follow–up of the Wisconsin Sleep Cohort, Sleep. 2008 Aug 1; 31(8): 1071""1078.

Attachment


GLOBENEWSWIRE (Distribution ID 1000453926)